For example, CPEB2 reduces p53 mRNA stability to promote renal cancer cell progression [12], and, on the other hand, enhances SRSF5 mRNA stability to mediate glioma-specific chemotherapeutic effects [22]. Here, TP53 is linked to renal carcinoma.